Lionmaster at The Lion:
"I would say AFFY prospect is 2x better than it was yesterday, reason is that Takeda is now taking over, no more unforseen costs or risk of total bankruptcy.
Even in bankruptcy, that royalty and milestone payment contract stay in place, and the shareholders get to hold perpetual patent right and future royalty and milestone payments from Takeda.
If Takeda just do $200M worldwide revenues per yearly, which is super conservative, that's a great amount of cash flowing in the Affymax coffer.
There's also a strong chance someone like Amgen may come knock on door this month".
WOW !!! This is great news. What's the worry then? I can wait for a while to get paid. Excellent post ! Keep up the good work.
just a rumors..I hoped,IT'LL HELP US OUT...We sank badly..no wat to get out from here...